Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

Objective: Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets. We investigated the therapeutic effects...

Full description

Bibliographic Details
Main Authors: Hani Jouihan, Sarah Will, Silvia Guionaud, Michelle L. Boland, Stephanie Oldham, Peter Ravn, Anthony Celeste, James L. Trevaskis
Format: Article
Language:English
Published: Elsevier 2017-11-01
Series:Molecular Metabolism
Subjects:
GLP-1
OCA
Combination therapy
NASH
Steatosis
Fibrosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877817303010

Similar Items

Similar Items